Ahmed Sallam
Concepts (428)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Vitrectomy | 31 | 2024 | 61 | 10.040 |
Why?
| Phacoemulsification | 18 | 2025 | 34 | 8.570 |
Why?
| Visual Acuity | 40 | 2025 | 144 | 8.440 |
Why?
| Macular Edema | 18 | 2024 | 29 | 8.240 |
Why?
| Cataract | 14 | 2024 | 45 | 7.180 |
Why?
| Triticum | 13 | 2024 | 17 | 6.320 |
Why?
| Cataract Extraction | 15 | 2024 | 32 | 6.170 |
Why?
| Intraoperative Complications | 17 | 2025 | 112 | 5.610 |
Why?
| Retinal Detachment | 15 | 2024 | 25 | 5.540 |
Why?
| Tomography, Optical Coherence | 21 | 2025 | 109 | 4.930 |
Why?
| Ophthalmology | 9 | 2025 | 33 | 4.620 |
Why?
| Diabetic Retinopathy | 10 | 2024 | 44 | 4.610 |
Why?
| Uveitis | 13 | 2024 | 23 | 4.130 |
Why?
| Postoperative Complications | 18 | 2024 | 1068 | 3.800 |
Why?
| Glaucoma | 9 | 2024 | 34 | 3.700 |
Why?
| Glucocorticoids | 16 | 2024 | 235 | 3.280 |
Why?
| Endophthalmitis | 11 | 2023 | 24 | 3.210 |
Why?
| Lens Implantation, Intraocular | 10 | 2025 | 23 | 3.210 |
Why?
| Epiretinal Membrane | 5 | 2024 | 10 | 3.190 |
Why?
| Retrospective Studies | 56 | 2025 | 6607 | 2.900 |
Why?
| Eye Infections, Bacterial | 8 | 2024 | 29 | 2.780 |
Why?
| Dexamethasone | 9 | 2023 | 438 | 2.630 |
Why?
| Humans | 135 | 2025 | 52483 | 2.530 |
Why?
| Comprehension | 7 | 2024 | 113 | 2.430 |
Why?
| Drug Implants | 9 | 2023 | 35 | 2.410 |
Why?
| Genotype | 12 | 2024 | 566 | 2.260 |
Why?
| Hordeum | 4 | 2022 | 6 | 2.240 |
Why?
| Syphilis | 5 | 2024 | 20 | 2.190 |
Why?
| Intraocular Pressure | 11 | 2024 | 59 | 2.190 |
Why?
| Fluorescein Angiography | 7 | 2024 | 34 | 2.180 |
Why?
| Vitreoretinal Surgery | 5 | 2024 | 8 | 2.040 |
Why?
| Droughts | 7 | 2024 | 12 | 2.030 |
Why?
| Diabetes Mellitus | 4 | 2022 | 316 | 1.900 |
Why?
| Eye Infections, Fungal | 6 | 2021 | 20 | 1.860 |
Why?
| Retinal Vessels | 3 | 2024 | 15 | 1.860 |
Why?
| Retinal Vein Occlusion | 6 | 2023 | 14 | 1.850 |
Why?
| Stress, Physiological | 6 | 2024 | 183 | 1.830 |
Why?
| Papilledema | 4 | 2022 | 27 | 1.820 |
Why?
| Retinitis Pigmentosa | 2 | 2024 | 8 | 1.740 |
Why?
| Aged | 44 | 2025 | 10121 | 1.690 |
Why?
| Middle Aged | 47 | 2025 | 13028 | 1.650 |
Why?
| Retinal Diseases | 8 | 2025 | 56 | 1.590 |
Why?
| Eye Diseases | 4 | 2025 | 29 | 1.580 |
Why?
| Pseudophakia | 6 | 2024 | 12 | 1.560 |
Why?
| Aged, 80 and over | 26 | 2025 | 3392 | 1.550 |
Why?
| Male | 64 | 2025 | 26761 | 1.530 |
Why?
| Angiogenesis Inhibitors | 7 | 2022 | 183 | 1.420 |
Why?
| Fluorocarbons | 3 | 2023 | 61 | 1.410 |
Why?
| Fibrin | 2 | 2023 | 10 | 1.390 |
Why?
| Intravitreal Injections | 15 | 2023 | 33 | 1.370 |
Why?
| Paracentesis | 2 | 2023 | 13 | 1.370 |
Why?
| Female | 61 | 2025 | 28171 | 1.370 |
Why?
| Databases, Factual | 11 | 2024 | 706 | 1.370 |
Why?
| Sclera | 2 | 2024 | 5 | 1.330 |
Why?
| Genome-Wide Association Study | 7 | 2024 | 186 | 1.300 |
Why?
| Tissue Plasminogen Activator | 2 | 2023 | 109 | 1.290 |
Why?
| Polymorphism, Single Nucleotide | 6 | 2024 | 505 | 1.270 |
Why?
| Macular Degeneration | 4 | 2024 | 28 | 1.250 |
Why?
| Lenses, Intraocular | 2 | 2022 | 7 | 1.230 |
Why?
| Follow-Up Studies | 15 | 2024 | 2279 | 1.220 |
Why?
| Retinal Perforations | 4 | 2023 | 7 | 1.170 |
Why?
| Choroid | 5 | 2024 | 14 | 1.150 |
Why?
| Retina | 7 | 2024 | 63 | 1.120 |
Why?
| Fractals | 2 | 2024 | 9 | 1.120 |
Why?
| Internet | 3 | 2024 | 263 | 1.110 |
Why?
| Iris Diseases | 3 | 2020 | 4 | 1.100 |
Why?
| Wet Macular Degeneration | 3 | 2022 | 6 | 1.090 |
Why?
| Adult | 32 | 2024 | 14161 | 1.080 |
Why?
| Quantitative Trait Loci | 5 | 2021 | 50 | 1.070 |
Why?
| Germination | 3 | 2023 | 7 | 1.060 |
Why?
| Candidiasis | 3 | 2021 | 113 | 1.050 |
Why?
| Linkage Disequilibrium | 4 | 2024 | 39 | 1.030 |
Why?
| Eye Injuries | 4 | 2024 | 24 | 1.020 |
Why?
| Societies, Medical | 3 | 2019 | 200 | 1.000 |
Why?
| Antihypertensive Agents | 3 | 2024 | 132 | 0.990 |
Why?
| Phenotype | 8 | 2024 | 789 | 0.970 |
Why?
| Retinopathy of Prematurity | 1 | 2025 | 17 | 0.960 |
Why?
| Genetic Variation | 4 | 2024 | 230 | 0.960 |
Why?
| Plant Diseases | 3 | 2019 | 12 | 0.950 |
Why?
| Muscarinic Agonists | 1 | 2024 | 11 | 0.930 |
Why?
| Pilocarpine | 1 | 2024 | 26 | 0.920 |
Why?
| Retinitis | 2 | 2022 | 5 | 0.920 |
Why?
| Egypt | 6 | 2024 | 19 | 0.920 |
Why?
| Lens Subluxation | 1 | 2024 | 2 | 0.910 |
Why?
| Vicia faba | 1 | 2024 | 1 | 0.910 |
Why?
| Limbus Corneae | 1 | 2024 | 8 | 0.900 |
Why?
| Endotamponade | 4 | 2018 | 9 | 0.900 |
Why?
| Lighting | 1 | 2024 | 5 | 0.890 |
Why?
| Ciliary Body | 1 | 2024 | 3 | 0.880 |
Why?
| Adaptation, Physiological | 2 | 2024 | 110 | 0.880 |
Why?
| Anterior Chamber | 1 | 2023 | 5 | 0.870 |
Why?
| Intensive Care Units, Neonatal | 1 | 2025 | 135 | 0.870 |
Why?
| Laser Coagulation | 1 | 2024 | 27 | 0.860 |
Why?
| Lens, Crystalline | 1 | 2024 | 20 | 0.860 |
Why?
| Triamcinolone Acetonide | 5 | 2011 | 15 | 0.850 |
Why?
| Ocular Hypertension | 2 | 2016 | 8 | 0.850 |
Why?
| Panuveitis | 2 | 2021 | 6 | 0.850 |
Why?
| Anesthesia, General | 3 | 2024 | 99 | 0.840 |
Why?
| Endoscopy | 1 | 2024 | 123 | 0.820 |
Why?
| Reproducibility of Results | 9 | 2024 | 1229 | 0.800 |
Why?
| Occlusive Dressings | 1 | 2022 | 6 | 0.800 |
Why?
| Cocaine-Related Disorders | 1 | 2025 | 207 | 0.800 |
Why?
| Incidence | 13 | 2024 | 1062 | 0.790 |
Why?
| State Medicine | 5 | 2023 | 17 | 0.790 |
Why?
| Rift Valley Fever | 1 | 2022 | 1 | 0.780 |
Why?
| HIV Seropositivity | 1 | 2022 | 28 | 0.780 |
Why?
| Optic Neuropathy, Ischemic | 1 | 2022 | 8 | 0.770 |
Why?
| Eye Foreign Bodies | 1 | 2022 | 6 | 0.760 |
Why?
| Enbucrilate | 1 | 2021 | 6 | 0.760 |
Why?
| Patient Education as Topic | 5 | 2024 | 321 | 0.760 |
Why?
| Tissue Adhesives | 1 | 2021 | 13 | 0.760 |
Why?
| Artificial Intelligence | 1 | 2023 | 115 | 0.760 |
Why?
| Vitreous Detachment | 2 | 2025 | 2 | 0.750 |
Why?
| Varicose Veins | 2 | 2019 | 19 | 0.720 |
Why?
| Risk Factors | 12 | 2025 | 3889 | 0.720 |
Why?
| Child | 17 | 2024 | 7248 | 0.710 |
Why?
| Health Services Accessibility | 1 | 2025 | 436 | 0.700 |
Why?
| Candida | 4 | 2020 | 63 | 0.700 |
Why?
| Choroiditis | 1 | 2020 | 9 | 0.700 |
Why?
| Treatment Outcome | 15 | 2024 | 5422 | 0.690 |
Why?
| Retinal Vein | 2 | 2019 | 2 | 0.660 |
Why?
| Photography | 4 | 2013 | 31 | 0.650 |
Why?
| Eyeglasses | 1 | 2019 | 9 | 0.650 |
Why?
| Cross-Sectional Studies | 8 | 2025 | 1678 | 0.650 |
Why?
| Surgical Instruments | 1 | 2019 | 28 | 0.640 |
Why?
| Trichoderma | 1 | 2019 | 1 | 0.640 |
Why?
| Crohn Disease | 1 | 2020 | 117 | 0.630 |
Why?
| Suture Techniques | 2 | 2022 | 60 | 0.620 |
Why?
| Vitreous Body | 6 | 2025 | 19 | 0.620 |
Why?
| Laser Therapy | 1 | 2019 | 82 | 0.610 |
Why?
| Fovea Centralis | 1 | 2018 | 5 | 0.610 |
Why?
| Basement Membrane | 1 | 2018 | 18 | 0.610 |
Why?
| Imaging, Three-Dimensional | 1 | 2019 | 154 | 0.600 |
Why?
| Vascular Endothelial Growth Factor A | 5 | 2022 | 182 | 0.590 |
Why?
| National Health Programs | 2 | 2015 | 18 | 0.590 |
Why?
| HIV Infections | 1 | 2022 | 389 | 0.580 |
Why?
| Fluocinolone Acetonide | 1 | 2017 | 5 | 0.570 |
Why?
| Vision Disorders | 5 | 2024 | 60 | 0.570 |
Why?
| Ophthalmic Solutions | 3 | 2024 | 20 | 0.560 |
Why?
| Air | 2 | 2016 | 23 | 0.550 |
Why?
| Chromosome Mapping | 5 | 2021 | 154 | 0.540 |
Why?
| Prospective Studies | 8 | 2024 | 2481 | 0.530 |
Why?
| Minerals | 1 | 2016 | 26 | 0.520 |
Why?
| Sodium Chloride | 1 | 2016 | 56 | 0.510 |
Why?
| Chorioretinitis | 3 | 2024 | 10 | 0.510 |
Why?
| Acetates | 1 | 2016 | 52 | 0.510 |
Why?
| Dissection | 1 | 2016 | 14 | 0.500 |
Why?
| Ophthalmologic Surgical Procedures | 1 | 2016 | 21 | 0.490 |
Why?
| Algorithms | 2 | 2023 | 672 | 0.490 |
Why?
| Anesthesia, Local | 1 | 2015 | 17 | 0.480 |
Why?
| Registries | 2 | 2018 | 581 | 0.480 |
Why?
| Adrenergic alpha-1 Receptor Antagonists | 2 | 2020 | 7 | 0.480 |
Why?
| Child, Preschool | 10 | 2024 | 4076 | 0.460 |
Why?
| United States | 10 | 2025 | 5192 | 0.460 |
Why?
| Microvessels | 2 | 2024 | 31 | 0.440 |
Why?
| Consumer Health Information | 2 | 2024 | 19 | 0.440 |
Why?
| Device Removal | 1 | 2014 | 82 | 0.420 |
Why?
| Treponema pallidum | 3 | 2024 | 9 | 0.410 |
Why?
| Macula Lutea | 2 | 2025 | 5 | 0.410 |
Why?
| Models, Theoretical | 1 | 2014 | 185 | 0.400 |
Why?
| Iris | 3 | 2022 | 5 | 0.400 |
Why?
| Alleles | 3 | 2023 | 276 | 0.380 |
Why?
| Scleral Buckling | 3 | 2023 | 4 | 0.370 |
Why?
| Prevalence | 4 | 2025 | 1006 | 0.370 |
Why?
| Physical Examination | 2 | 2013 | 99 | 0.370 |
Why?
| Optic Disk | 2 | 2021 | 20 | 0.370 |
Why?
| Mydriatics | 1 | 2011 | 12 | 0.370 |
Why?
| Electronic Health Records | 4 | 2024 | 268 | 0.360 |
Why?
| Microscopy | 1 | 2011 | 60 | 0.360 |
Why?
| Seasons | 2 | 2022 | 92 | 0.340 |
Why?
| Diagnostic Techniques, Ophthalmological | 2 | 2023 | 11 | 0.330 |
Why?
| Fibrinolytic Agents | 2 | 2023 | 128 | 0.320 |
Why?
| Anti-Bacterial Agents | 5 | 2024 | 807 | 0.320 |
Why?
| Intraoperative Period | 2 | 2019 | 46 | 0.320 |
Why?
| Basidiomycota | 2 | 2019 | 3 | 0.320 |
Why?
| Vision, Low | 2 | 2022 | 9 | 0.320 |
Why?
| Disease Resistance | 2 | 2019 | 9 | 0.320 |
Why?
| Fundus Oculi | 3 | 2024 | 24 | 0.310 |
Why?
| Lens Capsule, Crystalline | 2 | 2016 | 2 | 0.310 |
Why?
| Chromosomes, Plant | 3 | 2024 | 5 | 0.300 |
Why?
| Tonometry, Ocular | 2 | 2024 | 6 | 0.300 |
Why?
| Adrenergic alpha-Antagonists | 1 | 2008 | 27 | 0.300 |
Why?
| Silicone Oils | 3 | 2023 | 3 | 0.290 |
Why?
| Eye Infections, Viral | 1 | 2008 | 3 | 0.290 |
Why?
| Ocular Hypotension | 1 | 2008 | 2 | 0.290 |
Why?
| Eye Infections, Parasitic | 1 | 2008 | 3 | 0.290 |
Why?
| Choroid Neoplasms | 1 | 2007 | 6 | 0.290 |
Why?
| Suction | 1 | 2008 | 24 | 0.290 |
Why?
| Teaching Materials | 2 | 2024 | 31 | 0.280 |
Why?
| Physicians, Family | 1 | 2008 | 65 | 0.280 |
Why?
| Eye Burns | 1 | 2007 | 1 | 0.280 |
Why?
| Sulfonamides | 1 | 2008 | 133 | 0.270 |
Why?
| Hyaluronic Acid | 1 | 2007 | 38 | 0.270 |
Why?
| Anti-Infective Agents | 1 | 2008 | 107 | 0.260 |
Why?
| Adolescent | 9 | 2024 | 6739 | 0.260 |
Why?
| Genetic Markers | 2 | 2024 | 109 | 0.250 |
Why?
| Vaccination | 3 | 2024 | 298 | 0.250 |
Why?
| Young Adult | 8 | 2024 | 4329 | 0.240 |
Why?
| Prostaglandins, Synthetic | 1 | 2024 | 1 | 0.230 |
Why?
| Dry Eye Syndromes | 1 | 2024 | 11 | 0.230 |
Why?
| Salicylic Acid | 1 | 2024 | 5 | 0.230 |
Why?
| Trabeculectomy | 1 | 2024 | 9 | 0.230 |
Why?
| Administration, Topical | 1 | 2024 | 61 | 0.230 |
Why?
| Genes, Plant | 1 | 2024 | 11 | 0.230 |
Why?
| Glaucoma Drainage Implants | 1 | 2024 | 6 | 0.230 |
Why?
| Cohort Studies | 2 | 2022 | 1542 | 0.220 |
Why?
| Vitreoretinopathy, Proliferative | 1 | 2024 | 2 | 0.220 |
Why?
| Syphilis Serodiagnosis | 1 | 2024 | 4 | 0.220 |
Why?
| Melanoma | 1 | 2007 | 288 | 0.220 |
Why?
| Genome, Plant | 1 | 2024 | 10 | 0.220 |
Why?
| Garlic | 1 | 2024 | 5 | 0.220 |
Why?
| Abducens Nerve Diseases | 1 | 2024 | 7 | 0.220 |
Why?
| Proanthocyanidins | 1 | 2024 | 4 | 0.220 |
Why?
| Ciliary Arteries | 1 | 2024 | 3 | 0.220 |
Why?
| Burns, Chemical | 1 | 2024 | 9 | 0.220 |
Why?
| Haplotypes | 1 | 2024 | 92 | 0.220 |
Why?
| Nebraska | 2 | 2021 | 7 | 0.220 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 509 | 0.220 |
Why?
| Pseudotumor Cerebri | 1 | 2024 | 25 | 0.220 |
Why?
| Search Engine | 1 | 2023 | 10 | 0.220 |
Why?
| Propensity Score | 1 | 2024 | 154 | 0.220 |
Why?
| Glaucoma, Open-Angle | 1 | 2024 | 24 | 0.220 |
Why?
| Tattooing | 1 | 2023 | 5 | 0.210 |
Why?
| Geographic Atrophy | 1 | 2023 | 2 | 0.210 |
Why?
| Sex Workers | 1 | 2023 | 2 | 0.210 |
Why?
| Inflammation | 3 | 2022 | 641 | 0.210 |
Why?
| Gene-Environment Interaction | 2 | 2021 | 40 | 0.210 |
Why?
| Cultural Diversity | 1 | 2023 | 36 | 0.210 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2024 | 122 | 0.210 |
Why?
| Fibrinolysin | 1 | 2023 | 2 | 0.210 |
Why?
| Odds Ratio | 1 | 2025 | 558 | 0.210 |
Why?
| Self Report | 1 | 2024 | 210 | 0.210 |
Why?
| Drainage | 1 | 2023 | 87 | 0.210 |
Why?
| Schools, Medical | 1 | 2023 | 69 | 0.210 |
Why?
| Retreatment | 2 | 2014 | 58 | 0.210 |
Why?
| ROC Curve | 1 | 2023 | 253 | 0.200 |
Why?
| Dementia | 1 | 2024 | 134 | 0.200 |
Why?
| Patient Selection | 1 | 2024 | 259 | 0.200 |
Why?
| Faculty, Medical | 1 | 2023 | 91 | 0.200 |
Why?
| Vision Screening | 1 | 2022 | 11 | 0.200 |
Why?
| Subretinal Fluid | 1 | 2022 | 2 | 0.200 |
Why?
| Blood-Retinal Barrier | 1 | 2022 | 6 | 0.200 |
Why?
| Feasibility Studies | 1 | 2024 | 406 | 0.200 |
Why?
| Disease Management | 2 | 2021 | 188 | 0.200 |
Why?
| Sudan | 1 | 2022 | 2 | 0.200 |
Why?
| Privacy | 1 | 2022 | 18 | 0.200 |
Why?
| Health Literacy | 4 | 2024 | 132 | 0.200 |
Why?
| Cyanoacrylates | 1 | 2021 | 5 | 0.190 |
Why?
| Fibrin Tissue Adhesive | 1 | 2021 | 12 | 0.190 |
Why?
| Polymerase Chain Reaction | 1 | 2023 | 461 | 0.190 |
Why?
| Antibodies, Monoclonal, Humanized | 2 | 2015 | 236 | 0.190 |
Why?
| Recombinant Fusion Proteins | 1 | 2022 | 177 | 0.190 |
Why?
| Prednisone | 1 | 2022 | 102 | 0.190 |
Why?
| Eye Abnormalities | 1 | 2021 | 24 | 0.190 |
Why?
| Vision, Ocular | 1 | 2021 | 10 | 0.190 |
Why?
| Eye | 1 | 2021 | 25 | 0.190 |
Why?
| Infant | 5 | 2024 | 3733 | 0.180 |
Why?
| Disease Outbreaks | 1 | 2022 | 123 | 0.180 |
Why?
| Sensitivity and Specificity | 1 | 2023 | 891 | 0.180 |
Why?
| Tomography, X-Ray Computed | 2 | 2022 | 1165 | 0.180 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2024 | 221 | 0.180 |
Why?
| Prolapse | 1 | 2020 | 6 | 0.180 |
Why?
| Ecosystem | 1 | 2022 | 96 | 0.180 |
Why?
| Microsatellite Repeats | 1 | 2020 | 42 | 0.180 |
Why?
| Fungemia | 1 | 2021 | 38 | 0.180 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2024 | 595 | 0.180 |
Why?
| Oximetry | 2 | 2011 | 66 | 0.170 |
Why?
| Ophthalmoscopy | 1 | 2020 | 15 | 0.170 |
Why?
| Swine | 1 | 2021 | 428 | 0.170 |
Why?
| Carcinoma, Hepatocellular | 1 | 2022 | 202 | 0.170 |
Why?
| Retinal Pigment Epithelium | 1 | 2020 | 14 | 0.170 |
Why?
| Blindness | 2 | 2022 | 32 | 0.170 |
Why?
| Bacteria | 1 | 2022 | 228 | 0.170 |
Why?
| Substance Abuse, Intravenous | 1 | 2020 | 44 | 0.160 |
Why?
| Nanoparticles | 1 | 2021 | 160 | 0.160 |
Why?
| Fusariosis | 1 | 2019 | 6 | 0.160 |
Why?
| Plant Roots | 1 | 2019 | 30 | 0.160 |
Why?
| Fusarium | 1 | 2019 | 31 | 0.160 |
Why?
| Hepatitis C | 1 | 2020 | 79 | 0.160 |
Why?
| Referral and Consultation | 3 | 2013 | 292 | 0.160 |
Why?
| Liver Neoplasms | 1 | 2022 | 333 | 0.150 |
Why?
| Emergencies | 2 | 2009 | 81 | 0.150 |
Why?
| Antibiotic Prophylaxis | 1 | 2019 | 61 | 0.150 |
Why?
| MicroRNAs | 1 | 2022 | 387 | 0.150 |
Why?
| Animals | 3 | 2024 | 13505 | 0.150 |
Why?
| Water | 1 | 2019 | 82 | 0.150 |
Why?
| Equipment Design | 1 | 2019 | 293 | 0.150 |
Why?
| Gaucher Disease | 1 | 2018 | 17 | 0.150 |
Why?
| Surgical Wound Infection | 1 | 2019 | 118 | 0.140 |
Why?
| Genetic Linkage | 1 | 2017 | 25 | 0.140 |
Why?
| Recurrence | 2 | 2011 | 672 | 0.140 |
Why?
| Sulfur Hexafluoride | 1 | 2017 | 3 | 0.140 |
Why?
| Infant, Newborn | 1 | 2025 | 2867 | 0.140 |
Why?
| Treatment Failure | 1 | 2018 | 122 | 0.140 |
Why?
| Drug Therapy, Combination | 2 | 2016 | 395 | 0.140 |
Why?
| Eye Diseases, Hereditary | 1 | 2017 | 5 | 0.140 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2024 | 560 | 0.140 |
Why?
| Inheritance Patterns | 1 | 2017 | 22 | 0.140 |
Why?
| Fatty Acids | 1 | 2018 | 149 | 0.140 |
Why?
| Penicillins | 1 | 2017 | 28 | 0.140 |
Why?
| Carbonic Anhydrase Inhibitors | 2 | 2024 | 5 | 0.140 |
Why?
| Contrast Media | 1 | 2018 | 193 | 0.130 |
Why?
| Time Factors | 3 | 2020 | 2968 | 0.130 |
Why?
| Microsurgery | 2 | 2024 | 30 | 0.130 |
Why?
| Drug Combinations | 1 | 2016 | 132 | 0.130 |
Why?
| Video Recording | 1 | 2016 | 81 | 0.130 |
Why?
| Philippines | 1 | 2015 | 11 | 0.130 |
Why?
| India | 1 | 2015 | 68 | 0.120 |
Why?
| Anesthetics, General | 1 | 2015 | 4 | 0.120 |
Why?
| Visually Impaired Persons | 1 | 2015 | 1 | 0.120 |
Why?
| Dose-Response Relationship, Drug | 2 | 2016 | 1378 | 0.120 |
Why?
| England | 2 | 2012 | 58 | 0.120 |
Why?
| Anesthetics, Local | 1 | 2015 | 79 | 0.110 |
Why?
| Acute Disease | 2 | 2021 | 373 | 0.110 |
Why?
| Reading | 2 | 2024 | 73 | 0.110 |
Why?
| Microscopy, Acoustic | 1 | 2013 | 5 | 0.110 |
Why?
| Language | 2 | 2024 | 138 | 0.100 |
Why?
| Diagnosis, Differential | 3 | 2017 | 1046 | 0.100 |
Why?
| Glaucoma, Neovascular | 1 | 2012 | 2 | 0.100 |
Why?
| Infusions, Intravenous | 2 | 2017 | 220 | 0.100 |
Why?
| Syndrome | 2 | 2011 | 247 | 0.090 |
Why?
| Muscle Hypotonia | 1 | 2011 | 23 | 0.090 |
Why?
| Risk Assessment | 1 | 2016 | 1327 | 0.090 |
Why?
| Mutation | 1 | 2017 | 1347 | 0.090 |
Why?
| Risperidone | 1 | 2011 | 25 | 0.090 |
Why?
| Eye Hemorrhage | 1 | 2010 | 1 | 0.090 |
Why?
| Cranial Sinuses | 1 | 2010 | 8 | 0.080 |
Why?
| Carotid Artery Injuries | 1 | 2010 | 13 | 0.080 |
Why?
| Arteriovenous Fistula | 1 | 2010 | 28 | 0.080 |
Why?
| Prostaglandins F, Synthetic | 1 | 2009 | 1 | 0.080 |
Why?
| Anti-Inflammatory Agents | 1 | 2011 | 166 | 0.080 |
Why?
| Prednisolone | 1 | 2009 | 56 | 0.080 |
Why?
| Antipsychotic Agents | 1 | 2011 | 235 | 0.080 |
Why?
| Acetazolamide | 1 | 2008 | 17 | 0.080 |
Why?
| Oxygen | 1 | 2011 | 336 | 0.070 |
Why?
| Pupil | 1 | 2008 | 29 | 0.070 |
Why?
| Vitreous Hemorrhage | 1 | 2008 | 4 | 0.070 |
Why?
| Prostatic Hyperplasia | 1 | 2008 | 37 | 0.070 |
Why?
| Mass Screening | 1 | 2011 | 357 | 0.070 |
Why?
| Injections | 1 | 2008 | 61 | 0.070 |
Why?
| Electroretinography | 2 | 2018 | 16 | 0.070 |
Why?
| Models, Biological | 1 | 2011 | 735 | 0.070 |
Why?
| Cefuroxime | 1 | 2007 | 3 | 0.070 |
Why?
| Cefazolin | 1 | 2007 | 11 | 0.070 |
Why?
| Capsulorhexis | 1 | 2007 | 1 | 0.070 |
Why?
| Rupture | 1 | 2007 | 24 | 0.070 |
Why?
| Astigmatism | 1 | 2007 | 5 | 0.070 |
Why?
| Neoplasm Metastasis | 1 | 2007 | 243 | 0.070 |
Why?
| Chronic Disease | 1 | 2009 | 586 | 0.070 |
Why?
| Clinical Competence | 1 | 2008 | 406 | 0.060 |
Why?
| Chlorophyll | 1 | 2024 | 14 | 0.060 |
Why?
| Tissue Adhesions | 1 | 2025 | 35 | 0.060 |
Why?
| Dehydration | 1 | 2024 | 25 | 0.060 |
Why?
| Plant Leaves | 1 | 2024 | 44 | 0.060 |
Why?
| Reagins | 1 | 2024 | 3 | 0.060 |
Why?
| Posterior Eye Segment | 1 | 2024 | 3 | 0.060 |
Why?
| Sex Distribution | 1 | 2024 | 137 | 0.060 |
Why?
| Prosthesis Implantation | 1 | 2024 | 51 | 0.060 |
Why?
| Rumen | 1 | 2024 | 1 | 0.060 |
Why?
| Antibodies, Bacterial | 1 | 2024 | 30 | 0.060 |
Why?
| Tannins | 1 | 2024 | 3 | 0.060 |
Why?
| Fermentation | 1 | 2024 | 14 | 0.060 |
Why?
| Goats | 1 | 2024 | 13 | 0.060 |
Why?
| Diplopia | 1 | 2024 | 20 | 0.050 |
Why?
| Animal Feed | 1 | 2024 | 56 | 0.050 |
Why?
| Antifungal Agents | 1 | 2006 | 347 | 0.050 |
Why?
| Immunoglobulin G | 1 | 2024 | 195 | 0.050 |
Why?
| Anesthesia | 1 | 2024 | 71 | 0.050 |
Why?
| Surgical Flaps | 1 | 2024 | 110 | 0.050 |
Why?
| Homosexuality, Male | 1 | 2023 | 52 | 0.050 |
Why?
| Retinal Ganglion Cells | 1 | 2022 | 16 | 0.050 |
Why?
| Traction | 1 | 2021 | 8 | 0.050 |
Why?
| Seeds | 1 | 2021 | 16 | 0.050 |
Why?
| Reoperation | 2 | 2014 | 465 | 0.050 |
Why?
| Socioeconomic Factors | 1 | 2023 | 610 | 0.040 |
Why?
| Health Status Disparities | 1 | 2023 | 215 | 0.040 |
Why?
| Atrophy | 1 | 2020 | 45 | 0.040 |
Why?
| Plant Stems | 1 | 2019 | 13 | 0.040 |
Why?
| Emergency Service, Hospital | 1 | 2024 | 522 | 0.040 |
Why?
| Diet | 1 | 2024 | 587 | 0.040 |
Why?
| Gene Frequency | 1 | 2019 | 98 | 0.040 |
Why?
| Healthcare Disparities | 1 | 2023 | 299 | 0.040 |
Why?
| Pandemics | 1 | 2024 | 585 | 0.040 |
Why?
| Europe | 1 | 2019 | 87 | 0.040 |
Why?
| Molecular Sequence Annotation | 1 | 2018 | 28 | 0.040 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2022 | 857 | 0.040 |
Why?
| Glucosylceramidase | 1 | 2018 | 8 | 0.040 |
Why?
| Administration, Oral | 2 | 2011 | 451 | 0.040 |
Why?
| Enzyme Replacement Therapy | 1 | 2018 | 17 | 0.040 |
Why?
| Visual Fields | 1 | 2018 | 41 | 0.040 |
Why?
| Inbreeding | 1 | 2017 | 4 | 0.040 |
Why?
| Bread | 1 | 2017 | 3 | 0.040 |
Why?
| Crosses, Genetic | 1 | 2017 | 34 | 0.040 |
Why?
| Transplantation, Autologous | 1 | 2020 | 488 | 0.040 |
Why?
| Genotyping Techniques | 1 | 2017 | 21 | 0.040 |
Why?
| Prone Position | 1 | 2017 | 32 | 0.040 |
Why?
| Genes, Recessive | 1 | 2017 | 16 | 0.030 |
Why?
| Consanguinity | 1 | 2017 | 18 | 0.030 |
Why?
| Heterozygote | 1 | 2017 | 90 | 0.030 |
Why?
| Pedigree | 1 | 2017 | 125 | 0.030 |
Why?
| Recombinant Proteins | 1 | 2018 | 483 | 0.030 |
Why?
| DNA Mutational Analysis | 1 | 2017 | 180 | 0.030 |
Why?
| Genetic Association Studies | 1 | 2017 | 122 | 0.030 |
Why?
| Genetic Testing | 1 | 2017 | 129 | 0.030 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 182 | 0.030 |
Why?
| Rupture, Spontaneous | 1 | 2016 | 20 | 0.030 |
Why?
| Practice Guidelines as Topic | 1 | 2019 | 488 | 0.030 |
Why?
| Pregnancy | 1 | 2023 | 2680 | 0.030 |
Why?
| Survival Analysis | 1 | 2016 | 673 | 0.030 |
Why?
| Choroidal Neovascularization | 1 | 2013 | 19 | 0.030 |
Why?
| Gonioscopy | 1 | 2012 | 3 | 0.030 |
Why?
| Age Distribution | 1 | 2013 | 174 | 0.030 |
Why?
| Neovascularization, Pathologic | 1 | 2012 | 153 | 0.020 |
Why?
| Retinal Artery | 1 | 2011 | 4 | 0.020 |
Why?
| Coloring Agents | 1 | 2011 | 69 | 0.020 |
Why?
| Indocyanine Green | 1 | 2011 | 33 | 0.020 |
Why?
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2011 | 9 | 0.020 |
Why?
| Angiography | 1 | 2011 | 114 | 0.020 |
Why?
| Dopamine Antagonists | 1 | 2011 | 22 | 0.020 |
Why?
| Injections, Intraocular | 1 | 2010 | 2 | 0.020 |
Why?
| Regional Blood Flow | 1 | 2011 | 109 | 0.020 |
Why?
| Methylprednisolone | 1 | 2010 | 41 | 0.020 |
Why?
| Orbit | 1 | 2010 | 26 | 0.020 |
Why?
| Chemotherapy, Adjuvant | 1 | 2011 | 124 | 0.020 |
Why?
| Adrenal Cortex Hormones | 1 | 2011 | 116 | 0.020 |
Why?
| Schizophrenia | 1 | 2011 | 254 | 0.020 |
Why?
| Immunosuppressive Agents | 1 | 2011 | 243 | 0.020 |
Why?
| Sweden | 1 | 2007 | 10 | 0.020 |
Why?
|
|
Sallam's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|